Role of cell-free DNA for predicting incidence and outcome of patients with ischemic stroke

Table 1 Various biomarker panels in different stroke condition

Ref.	Panel	Source of cases	Source of marker	Panel of marker	Sensitivity/specificity (%)
Stamova et al[20], 2010	Gene panel	Ischemic stroke vs control	RNA, whole blood	BCL6, PYGL, RNASE2, S100A9, S100A12, S100P, SLC16A6,ARG1, CA4, CKAP4, ETS-2, HIST2H2AA	93/95
Montaner et al[21], 2008	Protein panel	Cardioembolic vs noncardioembolic stroke	Protein, plasma	D-dimer, BNP	87/85
Laskowitz et al[22], 2009	Protein panel	Ischemic + hemorrhagic stroke vs control	Protein, plasma	BNP, D-dimer, MMP9, S100B	86/37
Jickling and Sharp[23], 2011	Gene panel	Large vessel vs cardioembolic stroke	RNA, Whole Blood	FCRL1, FLJ40125, GRM5, GSTK1, HLA-DOA, IRF6, LHFP, LHFP, LOC284751, LRRC37A3, P2RX5, PIK3C2B, PTPN20A, TFDP1, TMEM19, TSKS, ZNF185, ZNF254, ADAMTSL4, AP3S2	100/96
Barr et al[24], 2010	Gene panel	Ischemic stroke vs control	RNA, whole blood	SCA4, ARG1, S100A12, ORM1, CCR7, CSPG2, IQGAP1, LY96, MMP9, ORM1	-
Montaner et al[25], 2011	Protein panel	Ischemic + hemorrhagic stroke vs control	Protein, plasma	D-dimer, MMP-9, Caspase-3, Chimerin, Secretagogin, sRAGE	17/98
Vanni et al[26], 2011	Protein panel	Ischemic stroke vs control	Protein, whole blood	BNP, D-dimer, MMP9, S100B	86/37
Sharma et al[27], 2014	Protein panel	Ischemic + hemorrhagic stroke vs control	Protein, plasma	S100A12, Metalloproteinase inhibitor-4, Prolactin, Eotaxin, EGFR	90/84